The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Immunol
Autores principales: Mastaglio, Sara, Ruggeri, Annalisa, Risitano, Antonio M., Angelillo, Piera, Yancopoulou, Despina, Mastellos, Dimitrios C., Huber-Lang, Markus, Piemontese, Simona, Assanelli, Andrea, Garlanda, Cecilia, Lambris, John D., Ciceri, Fabio
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7189192/
https://ncbi.nlm.nih.gov/pubmed/32360516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2020.108450
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares